top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
816_aicvd (8)_9_edited.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
f055739f-1956-41a1-8156-cda95d1fea9f.png
AI-CVD Bundle
Muscle and Fat Analysis.png
Liver Attenuation.png
Cardiac Chambers Volumetry.png
ٍEpicardial Fat .png
Bone Mineral Density (BMD) .png
coronaryArteryCalcification.png
Lung Density Report- High Attenuation Index.png
Thoracic Aorta and Pulmonary Artery Sizing .png
Aortic Wall Aortic and Mitral Valve Report.png
Lung Density Report- Low Attenuation Index.png
AI-CVD--.png
Frame 1000008286.png
Frame 1000008286.png
Frame 1000008287.png

What if a routine CAC scan could reveal more than calcium?

Aug 17
2 min read

Updated: Aug 26


ESC 2026 · 10 Scientific Presentations · Oral & Poster · 1/10

 

Going Beyond the Conventional Agatston Score with Agatston-2.0

Organised by: European Society of Cardiology (ESC) visual



A HeartLung.AI study within the Miami Heart Study explores how AI-driven Agatston-2.0 and cardiometabolic phenotyping can uncover signals associated with obstructive stenosis, high-risk plaque, and non-calcified plaque—all from a routine CAC scan.


Traditional CAC scoring is highly valuable for quantifying calcified coronary plaque, but it does not directly measure non-calcified plaque, high-risk plaque features, or obstructive coronary stenosis. This study investigated whether AI could extract additional information already contained within the CAC scan and use it to better identify these clinically important plaque phenotypes.



Going Beyond the Agatston Score


The study included 1,259 asymptomatic participants, ages 40–65, from the Miami Heart Study who underwent paired CAC and CCTA imaging.

HeartLung.AI's AI-CVD approach analyzed the CAC scans to derive a broad range of cardiometabolic and cardiovascular imaging biomarkers, including:


  • Epicardial, visceral, and skeletal muscle characteristics

  • Liver fat

  • Cardiac chamber volumes

  • Aortic and pulmonary artery dimensions

  • Coronary and thoracic aortic calcification

  • Pericoronary adipose tissue (PCAT) features

  • Additional calcium and plaque-related indices


These measurements were then evaluated against plaque phenotypes identified on CCTA, including obstructive stenosis, high-risk plaque features, and non-calcified plaque.



Key Findings

Across all three major plaque phenotypes, the comprehensive AI-CVD model outperformed models based on the traditional Agatston CAC score alone:

Obstructive stenosisAI-CVD achieved an AUC of 0.957, compared with 0.881 for Agatston CAC-only.

High-risk plaqueAI-CVD achieved an AUC of 0.789, compared with 0.626 for Agatston CAC-only.

Non-calcified plaqueAI-CVD achieved an AUC of 0.771, compared with 0.679 for Agatston CAC-only.

The differences were statistically significant across all three comparisons (p < 0.001).



Why This Matters


A CAC scan is traditionally interpreted primarily through the amount of coronary calcium it contains. But the CT images themselves contain substantially more anatomical and metabolic information.


By using AI to analyze multiple structures and tissue characteristics from the same examination, this study suggests that a routine CAC scan could potentially provide a much broader picture of cardiovascular and cardiometabolic health—including information associated with coronary disease that is not captured by the calcium score alone.


The results support a shift from viewing CAC CT as simply a calcium-scoring examination toward considering it as a richer source of imaging biomarkers for cardiovascular risk assessment.


One routine CAC scan. Multiple cardiometabolic biomarkers. A deeper view of coronary risk.

Download the full presentation below to explore the AI-CVD methodology, cardiometabolic biomarkers, comparative performance, and study findings.




Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page